Abstract Number: 2594 • ACR/ARHP Annual Meeting 2018
Median Time to Pain Improvement in Patients with Psoriatic Arthritis Treated with Tofacitinib
Background/Purpose: Pain is a core domain of psoriatic arthritis (PsA).1 Rapid, sustained pain reduction is a priority for patients (pts) and physicians when choosing treatment.…Abstract Number: 619 • ACR/ARHP Annual Meeting 2017
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). We examined tofacitinib efficacy in patients (pts) with active…Abstract Number: 620 • ACR/ARHP Annual Meeting 2017
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open‑Label, Long-Term Extension Study
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). Interim data up to January 2017 (database not locked) report the…Abstract Number: 623 • ACR/ARHP Annual Meeting 2017
Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). PsA is a heterogeneous disease and composite endpoints…Abstract Number: 880 • ACR/ARHP Annual Meeting 2017
Tofacitinib Treatment in Patients with Psoriatic Arthritis and Rates of Radiologic Progression According to Baseline CRP Levels: Results from a Phase 3 Clinical Study
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Here, we evaluate radiographic progression in PsA patients…Abstract Number: 884 • ACR/ARHP Annual Meeting 2017
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients with Psoriatic Arthritis: An Integrated Analysis across Phase 3 and Long-Term Extension Studies
Background/Purpose: Cardiovascular (CV) disease and cardiometabolic syndrome are common comorbidities/causes of mortality in patients (pts) with psoriatic arthritis (PsA). Tofacitinib is an oral Janus kinase…Abstract Number: 424 • ACR/ARHP Annual Meeting 2017
Re-Establishment of Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in Rheumatoid Arthritis Patients after Temporary Discontinuation
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assessed tofacitinib efficacy and safety after temporary discontinuation and…Abstract Number: 596 • ACR/ARHP Annual Meeting 2017
Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Safety and efficacy were investigated in 2 Phase…Abstract Number: 613 • ACR/ARHP Annual Meeting 2017
Effect of Tofacitinib on Efficacy and Patient-Reported Outcomes in Psoriasis Patients with Baseline Psoriatic Arthritis: A Pooled Analysis of 2 Phase 3 Studies
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). Up to 42% of patients (pts) with psoriasis…Abstract Number: 10L • ACR/ARHP Annual Meeting 2016
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors: OPAL Beyond, a Randomized, Double Blind, Placebo-Controlled, Phase 3 Trial
Dafna D Gladman1, William Rigby2, Valderilio F Azevedo3, Frank Behrens4, Ricardo Blanco5, Andrzej Kaszuba6, Elizabeth Kudlacz7, Cunshan Wang7, Sujatha Menon7, Thijs Hendrikx8 and Keith S Kanik7, 1University of Toronto, Toronto, ON, Canada, 2Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, 3Federal University of Parana and Edumed Health Research Center and Biotech, Curitiba, Brazil, 4Johann Wolfgang Goethe University, Frankfurt, Germany, 5Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, 6Specialstyczne Gabinety Lerkarskie "DERMED", Lodz, Poland, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of PsA. In this first study of tofacitinib in patients (pts) with active…Abstract Number: 1647 • ACR/ARHP Annual Meeting 2016
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The objective of this analysis was to report tofacitinib safety and tolerability…Abstract Number: 2983 • ACR/ARHP Annual Meeting 2016
Efficacy and Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, or Adalimumab in Patients with Active Psoriatic Arthritis and an Inadequate Response to Conventional Synthetic Dmards: A Randomized, Placebo‑Controlled, Phase 3 Trial
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). This study evaluated tofacitinib efficacy and safety vs placebo…Abstract Number: 1639 • ACR/ARHP Annual Meeting 2015
Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
Background/Purpose: Treatment options delivering sustained efficacy when given as monotherapy in RA are limited.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of…Abstract Number: 1640 • ACR/ARHP Annual Meeting 2015
Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). ORAL Scan was a 2-year, randomized, Phase 3, clinical trial…Abstract Number: 1645 • ACR/ARHP Annual Meeting 2015
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…
ACR Meeting Abstracts